Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Records Study Links Dementia-Related Brain Changes to Hospital Stays For Critical Illness

By Johns Hopkins Medicine | September 27, 2018

A Johns Hopkins study found that hospitalization, critical illness and major infection may diminish parts of the brain that are most commonly affected by Alzheimer’s disease.

Researchers at Johns Hopkins report that a novel analysis of more than a thousand patients adds to evidence that hospitalization, critical illness and major infection may diminish brain structures that are most commonly affected by Alzheimer’s disease.

Results of the study, published Sept. 24 in the Journal of the American Geriatrics Society, suggest — but do not prove — that critical illness and major infection can promote such brain structure changes and accelerate the process of cognitive decline, the researchers say.

Walker cautions that the findings may be limited due to undetected or misclassified billing codes that define diagnosis in the medical records; a lack of information about potentially relevant comorbidities such as delirium; and the “observational” nature of the study, which was not designed to — and cannot — determine or prove cause and effect.

But, he said, “The findings do indicate that hospitalization, infection and critical illness may well influence changes in brain regions that underlie dementia.” He went on to say that “in order to maintain brain health in older adulthood, it is important to maintain bodywide health. Some of the events that can land you in the hospital may serve as risk factors for dementia.”

To explore whether critical illness and infection were associated with brain structure changes underlying cognitive decline and dementia, the research team used data from the Atherosclerosis Risk in Communities Study (ARIC), which included MRI scans showing brain structure, as well as social, demographic and hospital information for a large cohort of participants followed over a 24 year period that included five medical exams and structured interviews.

The study originally enrolled nearly 16,000 participants ages 45 to 64 from Washington County, Maryland; Forsyth County, North Carolina; Minneapolis, Minnesota; and Jackson, Mississippi.

Using this dataset makes the team’s study especially rigorous, Walker says, because of the long follow-up period that allowed the research team to capture hospitalization events over many years. This is important, he notes, because the process of Alzheimer’s disease evolves over the course of decades and takes time to diagnose.

For its analysis, Walker’s team focused on a subset of ARIC subjects who received a brain MRI during the final medical exam in the study to look at evidence of atrophy and damage to so-called white matter — the part of the brain responsible for transmitting messages.

 Damaged white matter appears superwhite on a scan, similar to overexposure on a photograph, Walker explains, and was measured using an automated program. All participants who received this brain MRI were included in the analysis.

Data on hospitalization frequency was collected from five in-person exams, annual telephone contact with participants and a survey of medical records from hospital admissions throughout the ARIC study. The research team identified critical illness using internationally defined classification of disease codes, or ICD-9 codes, used for insurance billing purposes. Critical illness included shock, severe sepsis (blood infections), acute respiratory failure, hypotension, respiratory or cardiac arrest, and the need for cardiopulmonary resuscitation orprolonged ventilation. The team then also identified the number of major infections, including septicemia, other bacterial infection and pneumonia, the same way.

Of the 1,689 participants included in the analysis, 1,214 (72 percent) were hospitalized, 47 (4 percent) had a critical illness and 165 (14 percent) had a major infection. The participants’ age at the first visit was 52.7 years, 60 percent were women, 28 percent were African-American and 5 percent met criteria for dementia.

The research team found that hospitalization during the follow-up period, regardless of the reason, was associated with 9 percent greater white matter hyperintensity volume and significantly lower integrity of white matter microstructure.

Among the 1,214 hospitalized patients in the analysis, those who had one or more critical illness had a 3 percent smaller brain volume in brain regions such as the hippocampus that are implicated in Alzheimer’s disease. Major infection was associated with both smaller brain volume in regions vulnerable to Alzheimer’s disease (2 percent smaller) and 10 percent larger brain ventricle volume.

Although infection can, in some instances, cause critical illness, the research team found that infection alone (without critical illness) was associated with reduced brain volume later in life.

Walker and the research team say they plan to examine how each hospitalization event relates to inflammation in the brain and systemic inflammation. They suspect, based on a growing body of research, that events such as critical illness and infection can cause brain inflammation, which leads to the observed reduction in brain volume. Together, these brain changes are thought to set the stage for cognitive decline and Alzheimer’s disease, which is estimated to occur in one in every three older adults in the U.S.

Other authors on this paper were Rebecca Gottesman, Aozhou Wu, David Knopman and Charles Brown IV of Johns Hopkins; Thomas Mosley Jr. of University of Mississippi Medical Center; Alvaro Alonso of Emory University and Anna-Kucharska-Newton of the University of North Carolina.


Filed Under: Neurological Disease

 

Related Articles Read More >

Cerevance/Merck
Merck forges Alzheimer’s pact with Cerevance
Scholar Rock logo
Scholar Rock sees continued progress with apitegromab in spinal muscular atrophy
Beacon Biosignals
How EEG data and machine learning can inform drug development
depression
The pandemic is fueling the demand for natural alternatives to antidepressants

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50